Tecentriq: Regulatory submission in Japan for ovarian cancer in 2020 (Chugai) - Apr 23, 2020 - Q1 FY 2020 Results: Regulatory submission in Japan for early breast cancer in 2021; Regulatory submission in Japan for NSCLC (neoadjuvant) in 2023 or later
Japanese regulatory • Breast Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thoracic Cancer
|